PP_1170x120_10-25-21

Humira

Boehringer Ingelheim biosimilar Cyltezo OK’d by FDA

Boehringer Ingelheim biosimilar Cyltezo OK’d by FDA

RIDGEFIELD, Conn. —  Boehringer Ingelheim Pharmaceuticals Inc. has gained Food and Drug Administration approval for Cyltezo, a biosimilar of Humira from AbbVie Inc. Boehringer Ingelheim said Tuesday that Cyltezo (adalimumab-adbm) comes in a prefilled syringe and is indicated to treat a range of chronic inflammatory diseases, including moderate to severe active rheumatoid arthritis, moderate to